Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Weiguo Wan

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Journal of Molecular and Cellular Cardiology|January 25, 2022
The essential role for endothelial cell sprouting in coronary collateral growthAnurag Jamaiyar, Cody Juguilon, Weiguo Wan, et al.
Cells|January 21, 2023
The Roles of Bone Marrow-Derived Stem Cells in Coronary Collateral Growth Induced by Repetitive IschemiaMolly Enrick, Anurag Jamaiyar, Vahagn Ohanyan, et al.
RMD Open|January 31, 2023
Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled studyXiaomei Leng, Wei Lin, Shixue Liu, et al.
Annals of the Rheumatic Diseases|April 29, 2024
Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc)Minrui Liang, Lingbiao Wang, Xiaolong Tian, et al.
Rheumatology (Oxford, England)|February 3, 2026
Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 studyYu Xue, Lingyun Sun, Ning Zhang, et al.
Respirology (Carlton, Vic.)|April 15, 2026
Upadacitinib Versus Tofacitinib in Anti-MDA5-Positive Dermatomyositis With Interstitial Lung Disease: A Multi-Centre Cohort Study Emulating a Target TrialCan Xia, Wanlong Wu, Saisai Lu, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 26, 2023
Pathogenic Gene Spectrum and Clinical Implication in Chinese Patients with Lupus NephritisChangming Zhang, Xu Han, Ying Jin, et al.
The European Respiratory Journal|January 30, 2025
Effectiveness and safety of tofacitinib <i>versus</i> calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort studyWanlong Wu, Bingpeng Guo, Wenjia Sun, et al.
Frontiers in Pharmacology|December 28, 2020
Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time PointsJinmei Su, Mengtao Li, Lan He, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 21, 2020
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical TrialJinmei Su, Mengtao Li, Lan He, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Journal of Molecular and Cellular Cardiology|January 25, 2022
The essential role for endothelial cell sprouting in coronary collateral growthAnurag Jamaiyar, Cody Juguilon, Weiguo Wan, et al.
Cells|January 21, 2023
The Roles of Bone Marrow-Derived Stem Cells in Coronary Collateral Growth Induced by Repetitive IschemiaMolly Enrick, Anurag Jamaiyar, Vahagn Ohanyan, et al.
RMD Open|January 31, 2023
Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled studyXiaomei Leng, Wei Lin, Shixue Liu, et al.
Annals of the Rheumatic Diseases|April 29, 2024
Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc)Minrui Liang, Lingbiao Wang, Xiaolong Tian, et al.
Rheumatology (Oxford, England)|February 3, 2026
Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 studyYu Xue, Lingyun Sun, Ning Zhang, et al.
Respirology (Carlton, Vic.)|April 15, 2026
Upadacitinib Versus Tofacitinib in Anti-MDA5-Positive Dermatomyositis With Interstitial Lung Disease: A Multi-Centre Cohort Study Emulating a Target TrialCan Xia, Wanlong Wu, Saisai Lu, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 26, 2023
Pathogenic Gene Spectrum and Clinical Implication in Chinese Patients with Lupus NephritisChangming Zhang, Xu Han, Ying Jin, et al.
The European Respiratory Journal|January 30, 2025
Effectiveness and safety of tofacitinib <i>versus</i> calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort studyWanlong Wu, Bingpeng Guo, Wenjia Sun, et al.
Frontiers in Pharmacology|December 28, 2020
Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time PointsJinmei Su, Mengtao Li, Lan He, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 21, 2020
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical TrialJinmei Su, Mengtao Li, Lan He, et al.
Pageof 9